Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8977959 | 1.00 | L3MBTL1 (0.38) | L3MBTL1PSMD14PLA2G1BMMP2ATG4B | |
| SCHEMBL9400786 | 0.98 | PSMD14 (0.35) | L3MBTL1PSMD14PLA2G1BMMP2ATG4B | |
| SCHEMBL7361239 | 0.98 | PSMD14 (0.35) | L3MBTL1PSMD14PLA2G1BMMP2ATG4B | |
| SCHEMBL7351183 | 0.98 | PSMD14 (0.35) | L3MBTL1PSMD14PLA2G1BMMP2ATG4B | |
| Fluoride SCHEMBL10576296 | 0.96 | PSMD14 (0.34) | L3MBTL1PSMD14PLA2G1BMMP2ATG4B | |
| SCHEMBL7296246 | 0.89 | MAPT (0.33) | L3MBTL1LMNAHIF1APTPN1 | |
| SCHEMBL18050418 | 0.89 | L3MBTL1 (0.39) | L3MBTL1LMNAHIF1AGPR84 | |
| SCHEMBL18050409 | 0.89 | L3MBTL1 (0.39) | L3MBTL1LMNAHIF1AGPR84 | |
| SCHEMBL17261305 | 0.86 | L3MBTL1 (0.36) | L3MBTL1LMNAHIF1AGPR84 | |
| SCHEMBL7355201 | 0.83 | HTT (0.37) | L3MBTL1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371348-B9 | Oral care composiion | JOHNSON & JOHNSON CONSUMER INC (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-2371347-B1 | Oral care compositions | JOHNSON & JOHNSON CONSUMER INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10272022-B2 | Oral care compositions | JOHNSON & JOHNSON CONSUMER INC. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-2371348-B1 | Oral care composiion | JOHNSON & JOHNSON CONSUMER INC (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2389075-B1 | SUSTAINED RELEASE OF NUTRIENTS IN VIVO | NEW WORLD PHARMACEUTICALS LLC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20170202789-A1 | METHODS AND RELATED COMPOSITIONS FOR IMPROVED DRUG BIOAVAILABILITY AND DISEASE TREATMENT | NEW WORLD PHARMACEUTICALS, LLC (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170196784-A1 | ORAL CARE COMPOSITIONS | KENVUE BRANDS LLC | 2017-07-13 | — | — | US | disclosed |
| US-9636284-B2 | Oral care compositions | JOHNSON & JOHNSON CONSUMER INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9554586-B2 | Sustained release of nutrients in vivo | NEW WORLD PHARMACEUTICALS, LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-9538775-B2 | Sustained release of nutrients in vivo | NEW WORLD PHARMACEUTICALS, LLC (US) | 2017-01-10 | — | — | US | disclosed |
| WO-2002041765-A2 | BIODEGRADABLE BIOADHESIVE CONTROLLED RELEASE SYSTEM OF NANO-PARTICLES FOR ORAL CARE PRODUCTS | SALVONA L.L.C. (US) | 2002-05-30 | — | — | WO | disclosed |
| US-5980868-A | A PROTECTIVE COATINGS COMPRISING A CATIONIC SURFACE ACTIVE AGENTS, HYDROPHOBIC BARRIER-FORMING MATERIALS AND ANTIMICROBIAL COMPOUNDS | PROVSEAL LLC | 1999-11-09 | — | — | US | disclosed |
| US-5961958-A | BARRIER MATERIAL, TRANSFER AGENT COMPOSED OF CETYLAMINE, N-TALLOW-1,3-PROPANEDIAMINE, HEXETIDINE, OR CETYLPYRIDINIUM HALIDE | FOUR STAR PARTNERS (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0805672-A4 | METHODS, COMPOSITIONS, AND DENTAL DELIVERY SYSTEMS FOR THE PROTECTION OF THE SURFACES OF TEETH | HOMOLA ANDREW M (US) | 1999-06-30 | — | — | EP | disclosed |
| US-5888480-A | COMPOSITION CONSISTING OF LECITHIN AND WAX BARRIER MATERIAL AS TOOTHPASTE OR COATED ON SOLID SUBSTRATE | FOUR STAR PARTNERS (US) | 1999-03-30 | — | — | US | disclosed |
| EP-0805672-A1 | METHODS, COMPOSITIONS, AND DENTAL DELIVERY SYSTEMS FOR THE PROTECTION OF THE SURFACES OF TEETH | HOMOLA, Andrew M. (US) | 1997-11-12 | — | — | EP | disclosed |
| US-5665333-A | Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth | PROVSEAL LLC | 1997-09-09 | — | — | US | disclosed |
| WO-1996022078-A1 | METHODS, COMPOSITIONS, AND DENTAL DELIVERY SYSTEMS FOR THE PROTECTION OF THE SURFACES OF TEETH | HOMOLA ANDREW M (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5182101-A | Biguanides, Cationic Surfactants | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1993-01-26 | — | — | US | disclosed |
| US-4820507-A | PLAQUE INHIBITORS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1989-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272022-B2 | Oral care compositions | OSTC, CTRC, WASHC5 | HSP90AA1 3317/4885L3MBTL1 4513/4885PSMD14 1214/4885 |
| US-20170196784-A1 | ORAL CARE COMPOSITIONS | OSTC, CTRC, WASHC5 | HSP90AA1 3317/4885L3MBTL1 4513/4885PSMD14 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.